FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667074> ?p ?o ?g. }

• W4385667074 endingPage "e27633f0" @default.
• W4385667074 startingPage "e27633f0" @default.
• W4385667074 abstract "Topic: 26. Sickle cell disease Background: Limb ulcers are one of the most debilitating complications of Sickle Cell Diseases (SCD), greatly limiting the quality of life of these patients. Although Hydroxyurea (HU) is a fundamental element in the management of patients with SCD, its role of in the emergence or worsening of limb ulcers in SCD patients is still a matter of debate. Aims: This study aimed to assess the evolution of malleolar ulcers in these patients and seek possible associations of these outcomes with the use of HU. Methods: A retrospective analysis was performed of the medical records of 33 adult patients with SCD and identified as having ulcers in the lower limbs, treated at the UNICAMP Blood Center between 2000 and 2020. Their data were compiled regarding demographic characteristics, genotype, number and size of lesions, duration and outcome (complete healing/regression or maintenance/increase of the lesion at the time of the study), as well as the use of HU and dose. Results: Of the 33 patients, 29 (88%) were HbSS, 3 (9%) HbSC and 1 (3%) sickle cell/beta0-thalassemia being 15 (45.5%) women and 18 (54.5%) men; the mean age at the onset of the lesions was 40 (14-70) and 33 (19-51) years, respectively, with a mean time of evolution of 58 (1-240) months. Thirteen patients (40%) had more than 1 lesion simultaneously and 11 (33%) had bilateral involvement. During the period evaluated, 22 (67%) had a completely healed ulcer; 3 (9%) decrease in size; in 5 (15%) there was no change and in 3 (9%) there was an increase in size. 16 patients (48%) reported pain; 14 (42%) had some episode of infection and antibiotics were used by 20 patients (61%). The main treatment prescribed was dressing with healing agents (73%); 16 patients (48%) were using HU at the time the ulcer appeared. Comparing the 2 groups regarding the use of HU, there was no significant difference in: i) duration of lesions (with HU: median duration of 75 months (5-188), without HU: 38 (2-240), p=0.87, Mann-Whitney test), ii) outcome: improvement/complete healing or increase (p=0.68, Fisher’s Exact Test) or iii) average weekly dose (with improvement of lesions: 7.3g/week (5- 8.5) x no improvement: 7.81 (4.5-12.25), p=0.96, Mann-Whitney test). Of the 16 patients initially using HU, 7 (43.75%) had the drug discontinued by the assistant physician at the time the ulcer appeared, 6 (37.5%) had the dose maintained and 3 (18.75%) had increased dose due to other complications that justified the conduct. In addition, 8 patients initially without HU had its use indicated despite the occurrence of ulcer. Comparing the 7 patients who had their use of HU interrupted in relation to those who had their dose increased or started using it despite ulcers (n=11), there was no difference in terms of healing/decrease versus increase in lesions (p=0.59, Fisher’s exact test). Summary/Conclusion: We observed that the use of HU was not associated with a greater chance of worsening of malleolar ulcers. On the other hand, we speculate that discontinuation of the drug would tend to lead to an increase in the incidence of vaso-occlusive crises, which could consequently result in the recrudescence of the lesions. Therefore, the presence or emergence of ulcers should not be a limiting factor for the use of HU, since many patients do not experience worsening of the lesions after its introduction. This paradigm shift led our center to reconsider the suspension of Hydroxyurea in patients with malleolar ulcers, believing that the beneficial effect of the drug is greater than the possible negative impact on their emergence or maintenance.Keywords: Hydroxyurea, Sickle cell disease" @default.
• W4385667074 created "2023-08-09" @default.
• W4385667074 creator A5032989942 @default.
• W4385667074 creator A5052529953 @default.
• W4385667074 creator A5066555849 @default.
• W4385667074 creator A5067713063 @default.
• W4385667074 creator A5070092884 @default.
• W4385667074 creator A5092614012 @default.
• W4385667074 date "2023-08-01" @default.
• W4385667074 modified "2023-10-16" @default.
• W4385667074 title "P1446: HYDROXYUREA AND LIMB ULCERS: IS IT WORTH SUSPENDING? RETROSPECTIVE COHORT STUDY OF BRAZILIAN ADULT PATIENTS WITH SICKLE CELL DISEASE" @default.
• W4385667074 doi "https://doi.org/10.1097/01.hs9.0000972668.27633.f0" @default.
• W4385667074 hasPublicationYear "2023" @default.
• W4385667074 type Work @default.
• W4385667074 citedByCount "0" @default.
• W4385667074 crossrefType "journal-article" @default.
• W4385667074 hasAuthorship W4385667074A5032989942 @default.
• W4385667074 hasAuthorship W4385667074A5052529953 @default.
• W4385667074 hasAuthorship W4385667074A5066555849 @default.
• W4385667074 hasAuthorship W4385667074A5067713063 @default.
• W4385667074 hasAuthorship W4385667074A5070092884 @default.
• W4385667074 hasAuthorship W4385667074A5092614012 @default.
• W4385667074 hasBestOaLocation W43856670741 @default.
• W4385667074 hasConcept C126322002 @default.
• W4385667074 hasConcept C141071460 @default.
• W4385667074 hasConcept C167135981 @default.
• W4385667074 hasConcept C187212893 @default.
• W4385667074 hasConcept C195910791 @default.
• W4385667074 hasConcept C2779134260 @default.
• W4385667074 hasConcept C2781156865 @default.
• W4385667074 hasConcept C71924100 @default.
• W4385667074 hasConcept C72563966 @default.
• W4385667074 hasConceptScore W4385667074C126322002 @default.
• W4385667074 hasConceptScore W4385667074C141071460 @default.
• W4385667074 hasConceptScore W4385667074C167135981 @default.
• W4385667074 hasConceptScore W4385667074C187212893 @default.
• W4385667074 hasConceptScore W4385667074C195910791 @default.
• W4385667074 hasConceptScore W4385667074C2779134260 @default.
• W4385667074 hasConceptScore W4385667074C2781156865 @default.
• W4385667074 hasConceptScore W4385667074C71924100 @default.
• W4385667074 hasConceptScore W4385667074C72563966 @default.
• W4385667074 hasIssue "S3" @default.
• W4385667074 hasLocation W43856670741 @default.
• W4385667074 hasLocation W43856670742 @default.
• W4385667074 hasOpenAccess W4385667074 @default.
• W4385667074 hasPrimaryLocation W43856670741 @default.
• W4385667074 hasRelatedWork W2003938723 @default.
• W4385667074 hasRelatedWork W2047967234 @default.
• W4385667074 hasRelatedWork W2118496982 @default.
• W4385667074 hasRelatedWork W2439875401 @default.
• W4385667074 hasRelatedWork W2477714387 @default.
• W4385667074 hasRelatedWork W2603773853 @default.
• W4385667074 hasRelatedWork W3048921073 @default.
• W4385667074 hasRelatedWork W4221019750 @default.
• W4385667074 hasRelatedWork W4238867864 @default.
• W4385667074 hasRelatedWork W2525756941 @default.
• W4385667074 hasVolume "7" @default.
• W4385667074 isParatext "false" @default.
• W4385667074 isRetracted "false" @default.
• W4385667074 workType "article" @default.